How to buy Selecta Biosciences stock

Selecta Biosciences, Inc is a biotechnology business based in the US. Selecta Biosciences shares (SELB) are listed on the NASDAQ and all prices are listed in US Dollars. Selecta Biosciences employs 43 staff and has a trailing 12-month revenue of around 0.00.

Selecta Biosciences share price

Use our graph to track the performance of SELB stocks over time.

Selecta Biosciences shares at a glance

• Key figures

Information last updated 2021-04-23.

52-week range	$1.50 - $5.70
50-day moving average	$4.15
200-day moving average	$3.58
Wall St. target price	$8.00
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-1.85

Buy Selecta Biosciences shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Selecta Biosciences stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Selecta Biosciences, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Selecta Biosciences financials

Revenue TTM	$16.6 million
Gross profit TTM	$-37,908,000
Return on assets TTM	-26.8%
Return on equity TTM	0%
Profit margin	0%
Book value	$0.10
Market capitalisation	$439.4 million

TTM: trailing 12 months

Shorting Selecta Biosciences shares

There are currently 6.7 million Selecta Biosciences shares held short by investors – that's known as Selecta Biosciences's "short interest". This figure is 1% down from 6.7 million last month.

There are a few different ways that this level of interest in shorting Selecta Biosciences shares can be evaluated.

Selecta Biosciences's "short interest ratio" (SIR)

Selecta Biosciences's "short interest ratio" (SIR) is the quantity of Selecta Biosciences shares currently shorted divided by the average quantity of Selecta Biosciences shares traded daily (recently around 1.2 million). Selecta Biosciences's SIR currently stands at 5.43. In other words for every 100,000 Selecta Biosciences shares traded daily on the market, roughly 5430 shares are currently held short.

However Selecta Biosciences's short interest can also be evaluated against the total number of Selecta Biosciences shares, or, against the total number of tradable Selecta Biosciences shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Selecta Biosciences's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 Selecta Biosciences shares in existence, roughly 60 shares are currently held short) or 0.069% of the tradable shares (for every 100,000 tradable Selecta Biosciences shares, roughly 69 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Selecta Biosciences.

Find out more about how you can short Selecta Biosciences stock.

Selecta Biosciences share dividends

We're not expecting Selecta Biosciences to pay a dividend over the next 12 months.

Selecta Biosciences share price volatility

Over the last 12 months, Selecta Biosciences's shares have ranged in value from as little as $1.5 up to $5.7. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Selecta Biosciences's is 1.106. This would suggest that Selecta Biosciences's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Selecta Biosciences overview

Selecta Biosciences, Inc. , a clinical-stage biopharmaceutical company, researches and develops nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's proprietary pipeline includes enzymes therapies, gene therapies, and other products and product candidates affected by undesired immune responses. Its lead product is SEL-212 that is in Phase III clinical trials for the treatment of chronic refractory gout, as well as develops a product candidate to treat IgA-mediated diseases, including IgA nephropathy, linear IgA bullous dermatitis, IgA pemphigus, and IgA vasculitis. The company also engages in the development of gene therapy product candidates that are in preclinical development, including MMA-101, a product candidate for the treatment methylmalonic academia; SEL-313, a product candidate to treat ornithine transcarbamylase deficiency; SEL-399, a product candidate to indicate appropriate dose of ImmTOR in humans to reduce the formation of antibodies to AAV capsids; and other products for the treatment of pompe disease, duchenne muscular dystrophy, and limb-girdle muscular dystrophy. In addition, it develops a product candidate to treat primary biliary cholangitis. The company has license and collaboration agreements with Swedish Orphan Biovitrum; Spark Therapeutics; Massachusetts Institute of Technology; Shenyang Sunshine Pharmaceutical Co.

Frequently asked questions

• What percentage of Selecta Biosciences is owned by insiders or institutions?

  Currently 25.109% of Selecta Biosciences shares are held by insiders and 53.317% by institutions.

• How many people work for Selecta Biosciences?

  Latest data suggests 43 work at Selecta Biosciences.

• When does the fiscal year end for Selecta Biosciences?

  Selecta Biosciences's fiscal year ends in December.

• Where is Selecta Biosciences based?

  Selecta Biosciences's address is: 65 Grove Street, Watertown, MA, United States, 02472

• What is Selecta Biosciences's ISIN number?

  Selecta Biosciences's international securities identification number is: US8162121045

• What is Selecta Biosciences's CUSIP number?

  Selecta Biosciences's Committee on Uniform Securities Identification Procedures number is: 816212104